BioWorld Science

Feb. 16, 1999

View Archived Issues

Transkaryotic Therapies: Q4 and FY98 highlights

Read More

Eclipse to hold special shareholder meeting to consider merger with CardioGenesis

Read More

AxyS initiates phase Ib studies of APC-2059 in psoriasis

Read More

AxyS initiates phase Ib studies of APC-2059 in acute IBD

Read More

Health Canada approves first active wound-healing agent

Read More

NPS Pharmaceuticals: Q4 and year-end 1998 highlights

Read More

Agouron presents Women First study results at ROI conference

Read More

New agents for prion diseases available for licensing from NIH

Read More

Pharmacia & Upjohn: Q4 1998 highlights

Read More

Ilex Oncology: Q4 and year-end 1998 highlights

Read More

Nippon Shinyaku: Annual Report 1998

Read More

Imidazole cytokine-suppressive antiinflammatory compounds from SB

Read More

Astra discloses novel neuronal N-type calcium channel ligands

Read More

New ribose-based antibacterial agents in development at HMR

Read More

IL-1beta inhibitors from ADIR useful for inflammatory conditions

Read More

Novel, orally bioavailable anticoagulants discovered at Lilly

Read More

ZD-4522 enters accelerated phase III trial program

Read More

First pivotal trial results reported for marimastat; BB to assess implications for development

Read More

Fibrinogen antagonist does not prevent restenosis after stent implantation in dog model

Read More

Phase III trial data support leflunomide as useful RA treatment option

Read More

Corixa completes acquisition of Anergen

Read More

Licensing opportunity from VUFB: alpha2-adrenoceptor antagonist for BPH and heart failure

Read More

Clinical study elucidates mechanism of action of antiplatelet compound E-5510

Read More

Icos collaborates with Array BioPharma on new drug development

Read More

Company Profile: NewBiotics

Read More

Ontak available this month in U.S.

Read More